Efalizumab
![(Efalizumab) Monoclonal Antibody, Clone Hu1124 [Biosimilar] (CABT-Z629H) This Product Is for Research Use Only and Is Not Intended for Diagnostic Use](https://docslib.b-cdn.net/cover/9032/efalizumab-monoclonal-antibody-clone-hu1124-biosimilar-cabt-z629h-this-product-is-for-research-use-only-and-is-not-intended-for-diagnostic-use-1959032.webp)
![RAPTIVA [Efalizumab]](https://docslib.b-cdn.net/cover/9745/raptiva-efalizumab-3119745.webp)
Top View
- Efalizumab in the Treatment of Psoriasis
- Biological Agents Targeting Beyond TNF-Alpha
- Recent Biotherapies and Infections
- International Nonproprietary Names (Inn) for Biological and Biotechnological Substances
- (INN) for Biological and Biotechnological Substances
- FDA Approved Indications1-3
- Extended Efalizumab for Psoriasis Well Tolerated
- WO 2018/067987 Al 12 April 2018 (12.04.2018) W !P O PCT
- (12) United States Patent (10) Patent No.: US 9,446,134 B2 Maggio (45) Date of Patent: *Sep
- (12) United States Patent (10) Patent No.: US 9,683,047 B2 Smith Et Al
- Criteria for Non Formulary Use Of
- When and How to Switch Psoriasis Patients from Anti-TNF Therapy
- Aseptic Meningitis-Retention Syndrome Associated with Tocilizumab in a Patient with Idiopathic Multicentric Castleman Disease
- Biological Agents Targeting Beyond TNF-Alpha
- Ustekinumab Improves Nail Disease in Patients with Moderate-To-Severe Psoriasis: Results from PHOENIX 1 P
- Raptiva Withdrawal
- Customs Tariff - Schedule Xxi - 1
- Exploring Off-Label Use of Biologics for Dermatologic Indications